LVM Capital Management Ltd. MI Cuts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

LVM Capital Management Ltd. MI decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 38.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 1,061 shares of the medical research company’s stock after selling 654 shares during the period. LVM Capital Management Ltd. MI’s holdings in Thermo Fisher Scientific were worth $554,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. raised its holdings in Thermo Fisher Scientific by 2.1% in the first quarter. BlackRock Inc. now owns 31,423,285 shares of the medical research company’s stock valued at $18,111,439,000 after buying an additional 633,163 shares during the period. Morgan Stanley raised its holdings in Thermo Fisher Scientific by 17.7% in the fourth quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock valued at $6,459,629,000 after buying an additional 1,764,312 shares during the period. FMR LLC raised its holdings in Thermo Fisher Scientific by 1.7% in the first quarter. FMR LLC now owns 11,354,044 shares of the medical research company’s stock valued at $6,544,130,000 after buying an additional 194,602 shares during the period. Price T Rowe Associates Inc. MD grew its position in Thermo Fisher Scientific by 1.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,123,657 shares of the medical research company’s stock valued at $5,024,306,000 after acquiring an additional 161,344 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC grew its position in Thermo Fisher Scientific by 104,536.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after acquiring an additional 8,347,260 shares in the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded down $5.31 during mid-day trading on Friday, reaching $510.33. The company’s stock had a trading volume of 579,040 shares, compared to its average volume of 1,474,755. The firm has a market cap of $196.96 billion, a price-to-earnings ratio of 35.25, a PEG ratio of 2.41 and a beta of 0.77. The business has a 50 day moving average price of $540.37 and a 200-day moving average price of $541.88. The company has a current ratio of 1.42, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a twelve month low of $475.77 and a twelve month high of $609.85.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $5.15 EPS for the quarter, missing analysts’ consensus estimates of $5.43 by ($0.28). The business had revenue of $10.69 billion during the quarter, compared to analyst estimates of $10.99 billion. Thermo Fisher Scientific had a return on equity of 18.59% and a net margin of 13.14%. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.51 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 22.37 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 13th. Shareholders of record on Friday, September 15th will be paid a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 9.57%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 3,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $557.77, for a total value of $1,673,310.00. Following the sale, the executive vice president now directly owns 17,556 shares in the company, valued at $9,792,210.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Marc N. Casper sold 1,600 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $550.60, for a total transaction of $880,960.00. Following the sale, the chief executive officer now directly owns 135,330 shares in the company, valued at $74,512,698. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 3,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the sale, the executive vice president now owns 17,556 shares in the company, valued at $9,792,210.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,700 shares of company stock worth $15,799,270. 0.32% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. KeyCorp lowered their price objective on shares of Thermo Fisher Scientific from $710.00 to $640.00 in a research report on Thursday, May 25th. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $664.00 to $625.00 and set an “outperform” rating for the company in a research report on Thursday, July 27th. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. They issued a “buy” rating and a $625.00 price objective for the company. JPMorgan Chase & Co. raised their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 in a research report on Thursday, July 27th. Finally, Wells Fargo & Company raised their price target on shares of Thermo Fisher Scientific from $505.00 to $520.00 and gave the stock an “underweight” rating in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $631.71.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.